- JP-listed companies
- Kidswell Bio Corporation
- Financials
- FCF margin (%)
Kidswell Bio Corporation (4584)
Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
| Period End | FCF margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | 18.3 | -114.87% |
| Mar 31, 2020 | -123.1 | +197.48% |
| Mar 31, 2018 | -41.4 | -21.15% |
| Mar 31, 2016 | -52.5 |